The platinum analogues, cisplatin and carboplatin, are among the most widely used
chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity …

Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …

Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …

Background Lung cancer is the most commonly diagnosed cancer and the leading cause of
cancer death in both sexes worldwide. Approximately 50% of those diagnosed with lung …

Objectives Platinum-based chemotherapy is the mainstay of first-line (1L) therapy for
advanced non-small cell cancer (NSCLC). The objective of this study was to evaluate the …

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and
the treatment of advanced NSCLC relies on systemic treatments. During the last decade …

ATF2 is a transcription factor involved in stress and DNA damage. A correlation between
ATF2 JNK‐mediated activation and resistance to damaging agents has already been …

Chemotherapy based on platinum compounds is the standard treatment for NSCLC patients
with EGFR wild type, and is also used as second line in mutated EGFR patients …

Neoadjuvant Therapy in Non–Small Cell Lung Cancer - Surgical Oncology Clinics Skip to
Main Content Skip to Main Menu Advertisement Surgical Oncology Clinics Log in Register Log …

Lung cancer is a leading cause of cancer-associated mortality worldwide. The cisplatin
(DDP)‑based chemotherapy remains the foundation of treatment for the majority of patients …